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A B S T R A C T
The identification of pathological atrophy in MRI scans requires specialized training, which is scarce outside dedicated centers. We sought to investigate the clinical
usefulness of computer-generated representations of local grey matter (GM) loss or increased volume of cerebral fluids (CSF) as normalized deviations (z-scores) from
healthy aging to either aid human visual readings or directly detect pathological atrophy.
Two experienced neuroradiologists rated atrophy in 30 patients with Alzheimer's disease (AD), 30 patients with frontotemporal dementia (FTD), 30 with dementia
due to Lewy-body disease (LBD) and 30 healthy controls (HC) on a three-point scale in 10 anatomical regions as reference gold standard. Seven raters, varying in their
experience with MRI diagnostics rated all cases on the same scale once with and once without computer-generated volume deviation maps that were overlaid on
anatomical slices. In addition, we investigated the predictive value of the computer generated deviation maps on their own for the detection of atrophy as identified
by the gold standard raters.
Inter and intra-rater agreements of the two gold standard raters were substantial (Cohen's kappa κ > 0.62). The intra-rater agreement of the other raters ranged
from fair (κ=0.37) to substantial (κ=0.72) and improved on average by 0.13 (0.57 < κ < 0.87) when volume deviation maps were displayed. The seven other
raters showed good agreement with the gold standard in regions including the hippocampus but agreement was substantially lower in e.g. the parietal cortex and did
not improve with the display of atrophy scores. Rating speed increased over the course of the study and irrespective of the presentation of voxel-wise deviations.
Automatically detected large deviations of local volume were consistently associated with gold standard atrophy reading as shown by an area under the receiver
operator characteristic of up to 0.95 for the hippocampus region. When applying these test characteristics to prevalences typically found in a memory clinic, we
observed a positive or negative predictive value close to or above 0.9 in the hippocampus for almost all of the expected cases. The volume deviation maps derived
from CSF volume increase were generally better in detecting atrophy.
Our study demonstrates an agreement of visual ratings among non-experts not further increased by displaying, region-specific deviations of volume. The high
predictive value of computer generated local deviations independent from human interaction and the consistent advantages of CSF-over GM-based estimations should
be considered in the development of diagnostic tools and indicate clinical utility well beyond aiding visual assessments.
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1. Introduction
The accuracy of MRI-based diagnostics of neurodegenerative dis-
orders depends on the level of expertise of the involved radiologists
(Klöppel et al., 2008a). A key element in integrating imaging for the
diagnosis is to recognize combinations of regions that show signs of
pathological neurodegeneration. A recent study has shown that expert
neuroradiologists can accurately identify a range of neurodegenerative
disorders based on MRI, particularly when the information from mul-
tiple rating scales is integrated (Harper et al., 2016). However, outside
specialized centers, where the majority of cases is seen, expert neu-
roradiologists are unavailable and therefore computer-aided analysis
techniques may support the process of diagnosis.
Over the past decade, research in the field of computer-assisted
diagnosis had a strong focus on multivariate pattern recognition
methods that have successfully identified a wide range of pathological
conditions (Klöppel et al., 2012). Although the integration into the
routine of a memory clinic remains challenging (Klöppel et al., 2015),
their ability to separate different types of neurodegenerative diseases
from one another as well as from healthy aging and to predict the
conversion to dementia in individuals with mild cognitive impairment
has first been shown a decade ago (Adaszewski et al., 2013; Cuingnet
et al., 2011; Davatzikos et al., 2011; Davatzikos et al., 2008; Dukart
et al., 2013; Fan et al., 2008; Heister et al., 2011; Klöppel et al., 2008b;
Misra et al., 2009; Teipel et al., 2007; Vemuri et al., 2009; Vemuri et al.,
2008a; Vemuri et al., 2008b).
Despite the promising performance on study samples, several lim-
itations of these methods exist. These supervised machine-learning
techniques require training data from which they learn the diagnostic
separation and can introduce non-obvious and non-trivial biases
whenever training samples are not representative: Despite efforts for
data sharing, it will remain difficult to fulfill that requirement e.g. for
the various subtypes of e.g. Fronto-temporal dementia (FTD) and
Alzheimer's Disease (AD) and when considering the presence of mul-
tiple pathologies in the same individual (Lim et al., 1999; Toledo et al.,
2012) as well as MRI sequence parameters. High numbers of training
samples and good control of technical and demographic factors
(Abdulkadir et al., 2013; Abdulkadir et al., 2011) can reduce this pro-
blem to some extent, but the diagnostic accuracy in a clinical setting is
significantly lower than in research samples (Klöppel et al., 2015).
Rather than relying on the diagnostic output of a computerized tool,
this study aimed to evaluate the usefulness of computing voxel-wise the
tissue specific deviation from the distribution in normal controls after
controlling for e.g. age in order to provide the clinical rater with ad-
ditional quantitative information. This approach is an application of
well- established voxel-based-morphometry (VBM) (Ashburner and
Friston, 2000) and a fast and robust strategy to obtain local grey matter
(GM) and cerebro-spinal fluid (CSF) volumes of individual subjects. We
performed two analyses to study usefulness. In the first, we assessed the
added value of displaying deviations from the expected local tissue
volumes along with the native image to aid raters in the visual as-
sessment of MRI scans. We here defined usefulness as an increase in
performance which was measured either as agreement with the re-
ference atrophy rating, time required to perform the reading, and
consistency of each individual reader when (unknowingly) seeing the
same subject twice. The second analysis assessed the agreement of re-
gion-wise aggregated volume deviation scores directly with the gold
standard rating. To this end, we computed receiver-operator-char-
acteristics (ROCs) and report the positive and negative predictive value
for prevalences, typically observed in a memory clinic.
Atrophy was rated in five anatomically defined brain regions per
hemisphere, typically affected early in the course of neurodegenerative
dementias. As in our previous work (Klöppel et al., 2008a) raters dif-
fered in their level of experience with the rating of cerebral MRI scans.
All received a brief written instruction with examples how atrophy
should be identified and how the voxel-wise volume deviation maps
indicate atrophy. We expected experienced raters to show a higher
agreement with the gold standard rating and that the colored maps
would be the more useful the less experienced a rater is and improve
agreement with the gold standard as well as intra-rater reliability. Al-
though the display of additional information may require extra time to
interpret, we expected this to be outweighed by less ambiguous in-
formation. While changes in GM volume are more directly related to
disease-specific neurodegeneration, rating scales (e.g. medial temporal
lobe atrophy score (Scheltens et al., 1992)) often explicitly include a
widening of CSF-spaces as criterion. Additionally, and from a technical
viewpoint, the borders between CSF are better defined compared to
those between GM and white matter. We therefore included visualiza-
tions of deviations from local CSF volume in our analysis. We also ex-
pected that the visual presentation of volume deviations maps would
increase the consistency of ratings of individual readers and the sub-
jective level of diagnostic confidence. In line with previous work
(Harper et al., 2016), we expected the highest agreement with the gold
standard raters in the medial temporal cortex. We included subjects
with dementia due to AD, FTD and dementia due to Lewy body disease
(LBD) as well as healthy older individuals (HC). The group with LBD
was included for consistency with our earlier work (Klöppel et al.,
2015) and that of others (Harper et al., 2016) and although LBD-related
changes on T1-weighted MRI are subtle.
2. Methods
2.1. Study data
Structural MRI from 120 subjects3 (30 HC, 30 AD, 30 FTD and 30
LBD) were acquired in Freiburg, Munich, and Leipzig or were taken
from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database
(adni.loni.usc.edu) (Mueller et al., 2005). The ADNI was launched in
2003 as a public-private partnership, led by Principal Investigator Mi-
chael W. Weiner, MD. The primary goal of ADNI has been to test
whether serial magnetic resonance imaging (MRI), positron emission
tomography (PET), other biological markers, and clinical and neu-
ropsychological assessment can be combined to measure the progres-
sion of mild cognitive impairment (MCI) and early AD. For up-to-date
information, see www.adni-info.org.
In order to avoid a confound between diagnostic category and
scanning parameters, ten cases with AD, LBD, ten controls, and six cases
with FTD were provided from Freiburg with identical scanning para-
meters and supplemented with external data to fill each category. The
overview of sociodemographic information is listed on Table 1.
Participants from all diagnostic groups showed clinical and bio-
marker patterns consistent with their respective diagnosis. Specifically,
HC from Freiburg were included if their Montreal Cognitive Assessment
(MoCA) score was ≥26 (Nasreddine et al., 2005) and their Beck's De-
pression Inventory-II (Beck et al., 1996) was ≤13. For the ADNI, HC
were included if cognitive functioning above education adjusted cut-
offs in the Logical Memory II subscale from the Wechsler Memory
Scale–Revised was documented, their Geriatric Depression Scale was
≤6, their MMSE score was between 24 and 30 (inclusive), and their
CDR was 0 (with a sum-of-box score of 0). We used an additional in-
dependent sample of healthy controls to estimate the normative range
of GM and CSF volumes (see Section 2.4 for details).
Patients with AD all met clinical criteria for probable AD dementia
with biomarker evidence. They all had clinical T1w MRI and had un-
dergone 18fluorodeoxyglucose (18F-FDG) or amyloid PET. The bio-
marker patters clearly indicated AD pathology according to established
criteria (McKhann et al., 2011). Patients with AD from the ADNI sample
3 One case with FTD appeared twice in the data set. The two scans from
different visits had different patient identifiers. This was coincidently found
after the analyses were completed.
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additionally had a CDR of 0.5–1. Patients with Lewy body disease all
presented with two or more clinical core features and met criteria for
probable LBD (McKeith et al., 2017) and, additionally, showed reduced
18F-FDG uptake (Minoshima et al., 2001; Yong et al., 2007). A subset of
20 cases has been previously reported (Perneczky et al., 2007). We
recruited a mixed sample of cases with FTD. Patients with FTD met
criteria (Neary et al., 1998) for either probable behavioural-variant
frontotemporal dementia (bvFTD) with frontal and/or anterior tem-
poral hypometabolism on 18F-FDG PET and frontal and/or anterior
temporal atrophy on MRI (Rascovsky et al., 2011) or for semantic de-
mentia (SD) that is characterized by predominant anterior temporal
hypoperfusion or hypometabolism on PET (Gorno-Tempini et al.,
2011). A subset of cases classified with FTD has been previously re-
ported (Dukart et al., 2011; Frings et al., 2010).
2.2. Image acquisition
Sagittal T1-weighted 3D magnetization prepared rapid gradient
echo (MPRAGE) sequences (approximately 1× 1×1mm3 resolution)
were acquired in Freiburg, Leipzig and Munich on different types of 1.5
and 3 Tesla Siemens scanners, each with a standard head coil, or were
obtained from the ADNI, being acquired at 1.5 or 3 Tesla magnetic field
strength. The MPRAGE sequences were converted to NIfTI-2 format,
and the filenames were pseudonymised before further processing.
2.3. Data processing
All T1 weighted images were processed identically. For the voxel-
wise analysis, we generated spatially normalized probability maps of
GM and CSF using SPM12 segmentation (Ashburner and Friston, 2005)
and non-linear registration algorithms (Ashburner and Friston, 2011).
Normalized and modulated images were smoothed with a
3× 3×3mm FWHM Gaussian kernel. The default setting was used for
processing and the modulated warped tissues of GM and CSF after
smoothing were used for the subsequent analyses.
2.4. Estimation of normalized local GM/CSF volumes and display of GM/
CSF atrophy indices
At every voxel of each individual, we computed two volume de-
viation scores, one for GM and one for CSF. The score indicated the
normalized deviation from the expected mean given the subject's age,
sex, and intracranial volume. It was defined as the z-score of the re-
sidual GM/CSF after correction for covariates as follows. We adjusted
the quantity of GM and CSF linearly for effects of age, sex, and total
intracranial volume based on the reference population using ordinary
least squares estimation of regression parameters and the residual
variance as estimate of uncertainty. To this end, three hundred sixty-
two healthy controls from the ADNI study were included to estimate
healthy aging based on a large population and the expected GM/CSF
volumes were subtracted from the measured volume (Dukart et al.,
2011). This reference data was acquired on a variety of scanners from
different vendors, field strengths, and with different receiver head coil
configurations. The residual variance was computed using the same
data and we assumed the variance to be homoscedastic, meaning that it
was assumed to be equal regardless of the subject's characteristics such
as age or sex. Formally, the atrophy scores aGM(v,s) and aCSF(v,s) for GM
and CSF in the reference MNI space at voxel v of subject s were defined
as
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where s and v indicate the subject and voxel location, respectively, y is
the measured local volume of GM or CSF, x the predictors (age, sex,
TIV), the estimated parameters of the linear model, and the esti-
mated residual variance. The parameters were estimated with or-
dinary least squares method. Note that the parameter estimates at each
voxel v were the same for all subjects since these scores and the para-
meters were estimated with coregistered GM/CSF tissue probability
maps and were then transformed to native space for the visualization.
We assumed that low normalized local GM volumes and high nor-
malized local CSF volumes were particularly informative to rate
atrophy and discarded changes in the opposite direction. We chose a
threshold of two standard deviations from which on we displayed de-
viations per voxel. Voxels with GM atrophy score larger than 2 (cor-
responding to z-scores smaller than −2) were displayed in four cold
colours ranging from dark to light blue. Voxels with CSF-based devia-
tion scores larger than 2 (corresponding to z-scores larger than 2) were
displayed in four warm colours ranging from dark red to yellow. In the
rare cases where voxels had high GM and high CSF atrophy scores si-
multaneously (partial volume effects), only the colour for GM atrophy
was displayed. To further reduce clutter, only clusters of at least five
voxels with atrophy scores above 2 were shown and only in voxels
where the average local GM/CSF volume of the healthy population was
above 0.5. An example of a resulting overlay is shown in Fig. 1.
2.5. Reading
The seven individual readers were presented with scrollable sec-
tions of the T1 image (Fig. 1) twice, either with or without visualization
of atrophy scores of GM and CSF. We made the assumption that in
general the readers would not recognize an already seen subject and
remember the rating that they gave for the individual regions, thus that
two readings of the same subject once with and once without visuali-
zation of atrophy scores would be independent. Furthermore, we made
the assumption that seeing the same image twice with or twice without
visualization of atrophy scores would be independent given a certain
interval between both. Thus, to avoid an immediate repetition of the
same image, images were presented in two blocks without repetitions in
the same block. To measure intra-rater reliability, 30 scans with and 30
scans without atrophy scores were shown twice in the same block. In
total, each individual reader reviewed 300 scans and 3000 single region
ratings (5 regions, 2 hemispheres).
No clinical information apart from age and sex was provided to the
Table 1
Sociodemographic characterization of the study cohorts.
Healthy controls Alzheimer's disease Lewy-body dementia Frontotemporal dementia
Mean SD Mean SD Mean SD Mean SD
n (m/f) 13/17 14/16 14/16 11/19
Age (years) 72.4 4.4 71.6 7.4 72.2 7.7 65.7 7.8
Education (years) 16.7 2.9 14.8 2.4 10.9 2.4 11.1 3.7
MMSE 29.0a 1.5 23.2 3.2 22.1 3.2 22.8 3.4
Note: SD= standard deviation, MMSE=Mini Mental Status Examination
a For n=6, no MMSE was available but cognitive functioning was evaluated with the Montreal Cognitive Assessment (MoCA, Nasreddine et al. (2005)). MoCA
scores were converted into MMSE scores according to Roalf et al. (2013).
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readers. Atrophy in ten regions had to be rated on a scale with three
levels (0=normal; 1= borderline atrophy; 2= pathological atrophy).
The instructions were limited to four pages that were submitted to the
raters without further comments. Each page showed one example for
each level of atrophy of one or two regions. Examples of temporo-lat-
eral and frontal regions were shown on the same page and examples of
the remaining three regions were shown on separate pages. The scores
were adapted from established rating scales. Hippocampus atrophy was
adapted from the medial temporal atrophy (MTA) score proposed by
Scheltens et al. (1992). MTA scores≤ 1 were translated to no atrophy,
MTA score= 2 was translated to borderline atrophy, and MTA
score≥ 3 was translated to pathological atrophy. The parietal atrophy
rating followed the rating proposed by Koedam et al. (2011). Koedam
score 0 and Koedam score 1 were translated to no atrophy and bor-
derline atrophy, respectively. Koedam score two or larger were trans-
lated to pathological atrophy in our study. Frontal and lateral temporal
atrophy was rated following Davies et al. (2009). Scores 0 and 1 were
equivalent in the original and our study and higher scores in the ori-
ginal scale were translated to pathological atrophy in our study. As
there was no established rating scale for occipital atrophy available, we
adapted the principle of evaluating prominent structures of the sub-
arachnoid-space and ventricular system as used in the previously
mentioned rating scales. As the calcarine fissure is the major CSF-con-
taining structure within the occipital lobe MRI examples of a normal
appearing, a slightly widened, and a definitely widened calcarine fis-
sure were added to the instructions. As there was no established rating
scale for occipital atrophy available, we adapted the principle of eval-
uating prominent structures of the subarachnoid-space and ventricular
system as used in the previously mentioned rating scales. As the cal-
carine fissure is the major CSF-containing structure within the occipital
lobe MRI examples of a normal appearing, a slightly widened, and a
definitely widened calcarine fissure were added to the instructions.In
addition to the atrophy rating, one of four mutually exclusive diagnoses
had to be picked. Responses on the diagnostic decision will be reported
separately. All fields had to be completed before the next subject was
shown and raters could not go back to previously presented scans.
Samples with and without deviation maps were shown in a random
order fix across readers. As gold standard raters did not see z-scores,
they received all images in one block of 150.
Both gold standard raters were trained neuro-radiologists with>
15 years of experience in the field. The other raters deliberately had a
wide range of expertise ranging from third year of specialization to
10+ years of experience as fully trained doctors.
To test whether less experienced readers would benefit more from
displayed deviation maps, we asked them to indicate the number of
brain scans for which they would rate the level of atrophy in a normal
workweek. All readers received a brief manual which explained the
orientation of the images (left/right) and that cold colours would in-
dicate GM loss and warm colours an increase in local CSF volume. Next,
the manual explained the use of the response field seen on the left side
of Fig. 1. Readers were also reminded that the age of each subject was
displayed. We presented a set of seven additional scans (not included in
the evaluation set) to familiarize each reader with the system. After
completing all ratings, readers were asked to indicate if they considered
the display of voxel-wise deviations helpful in respect to speed and
accuracy when reaching a decision on atrophy and diagnosis.
2.6. Evaluation of the added value of displaying computer assisted atrophy
reading
We studied potential benefits of displaying atrophy scores alongside
the plain structural MRI in the three categories accuracy, speed, and
retest-reliability.
To quantify the agreement between each individual rater and the
Fig. 1. Web interface for readers showing T1 image, atrophy scores, rating questionnaire, and basic demographic information. The interface allowed to scroll through
the slices of the structural MR image in all orthogonal views, to adjust the contrast and to increase each subpanel to full-screen. The sections showing the atrophy
scores (bottom right on this panel) were static but could also be enlarged to fill the screen.
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gold standard reading, we first excluded samples which one gold
standard reader rated as normal (0) and the other rated as clearly pa-
thological (2). Of note, the remaining regions of the scan remained in
the analysis and no regions were excluded for analyses of speed and
intra-rater agreement detailed below. Next, we defined three cate-
gories: full agreement required both gold standard-readers and the in-
dividual reader to exactly agree. Partial agreement additionally in-
cluded cases when the individual rater agreed with one of the gold
standard readers. We considered the agreement to be at chance level at
20% for full agreement (3 out of 15 valid combinations of ratings) and
at 47% (7 out 15) for the more lenient criterion (i.e. partial or full
agreement). Cases for which the individual rater disagreed with both
gold standard readers where defined as no agreement.
We used a paired t-test to identify a difference in accuracy with and
without atrophy scores. In cases that were presented twice as part of the
intra-rater reliability analysis, we used only the ratings of the first
presentation for the evaluations of accuracy. Although the atrophy
reading and the computation of the agreement of the individual read-
ings with the gold standard was done separately for left and right
hemisphere, we pooled the results over both hemispheres to simplify
the presentation of the results.
We performed a Pearson correlation to test for the expected positive
association between the level of previous experience in MRI reading
and the agreement with the gold standard and used Fisher's r2z test to
identify significant differences in the regression slope. Specifically, with
ratings based on native MRI, we expected more experienced raters to
perform better but that this correlation would be absent or weaker
when atrophy scores are displayed alongside the native MRI.
The time to complete the reading of a single volume was registered
during the experiment and included the MRI based differential diag-
nosis. Readers had the possibility to pause the reading which resulted in
a black screen and interrupted the timing. The participants were not
given any instructions about how quickly to finish.
Retest-reliability was assessed by showing a random subset of 30
volumes with and 30 volumes without visualization of deviation maps
in both blocks. Based on the ratings of the repeated volumes, we as-
sessed the test-retest agreement using Cohen's Kappa (κ) with quadratic
weight (Cohen, 1968) to account for the ordinal scale of the atrophy
codes. We computed κ for the repeated ratings once with and once
without visualization of the z-score deviation maps. Cohen's κ is usually
used to measure inter-rater reliability due to the assumption of in-
dependent observations. We minimized the dependency of two ob-
servations performed by the same reader rating the same sample by
using the two-block design detailed in Section 2.5. However, we cannot
exclude the possibility of dependencies, thus we acknowledge that the
estimation of the intra-rater agreement by the measure κ is possibly too
high. We also report the intra-rater reliability as percent exactly iden-
tical ratings as a more intuitively accessible measure that, however, is
insensitive to the extend of the disagreement and the frequencies of
ratings.
2.7. Usefulness of atrophy scores alone
Besides evaluating the benefits of the z-scores in assisting the human
visual reading, we were interested how much value these scores would
provide by themselves in informing about region-specific atrophy. For
this analysis we focused on cases with a clear rating result and excluded
regions where the gold standard readers fully disagreed and those
frontal
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Fig. 2. Distribution of atrophy readings per region and diagnostic category by the two gold standard readers. Regions which one reader identified as normal and the
other as borderline (0,1) entered the same category as two normal ratings (0,0). Accordingly pathological atrophy identified by just one reader (1,2) was assigned the
same category as two atrophy ratings (2,2).
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where both agreed that the atrophy was borderline. Regions with one
gold standard rating “zero” and another rating of “one” were graded as
“zero”, one rating of “one” and another rating of two lead to an overall
rating of two. Then, we computed for both tissue types (GM and CSF)
the volume of voxels with deviations of more than two standard de-
viations separately for each region in each hemisphere to express the
grade of atrophy in that particular region. Two standard deviations
were used as cut-point when visually indicating deviations to the in-
dividual raters in the first part of the study and thus were kept for
consistency. We report receiver operator characteristics (ROC) curves
as well as the positive predictive value (PPV), negative predictive value
(NPV), sensitivity (SE) and specificity (SP) at the threshold corre-
sponding to a maximum of the product of SE and SP. To rate the clinical
usefulness, we also report the rate of positive or negative predictions
(RPP, RNP). The RPP/RNP are the proportions of the population that
have a score higher/lower than the threshold for which the PPV/NPV is
reported. The RPP/RNP thus indicate the proportion of cases for which
the presence/absence of atrophy can be predicted with the reported
PPV/NPV. Given the high prevalence of relatively rare dementia cases
in our sample, the PPV would be unrealistically high. We thus com-
puted PPV and NPV for prevalences expected in a memory clinic (Alladi
et al., 2011; Claus et al., 2016). Specifically, we assumed the following
distribution of HC: 34%, AD: 38%, FTD: 19%, LBD: 9%. For each region
and diagnosis, we derived the prevalence of atrophy from the ratings of
our gold standard readers as reported in Fig. 2. The prevalence of di-
agnoses and the diagnosis-dependent proportion of atrophy in each
region were combined to yield for each region the expected proportion
of atrophy as
p p p p p
p p
p HC p
(atrophy | region) (AD) (atrophy | AD) (FTD) (atrophy | FTD)
(LBD) (atrophy | LBD)
( ) (atrophy | HC)
= +++
where p(D) indicates the expected proportion of cases with diagnosis D
as given by the field of application and p(atrophy|D) indicates the
proportion of atrophy given the diagnosis D as found in this study. The
positive predictive value of atrophy for the hypothesized clinical (rather
than study-specific) population thus was
PPV SE p
SE p SP
p
(region) (region) (atrophy | region)
(region) (atrophy | region) (1 (region)) (1
(atrophy | region))
= +
where SE (sensitivity) SP (specificity) were chosen at the atrophy score
threshold that maximized the product of sensitivity and specificity.
3. Results
All raters completed the full data set. Subjectively, individual raters
found the display of voxel-wise deviations helpful to increase the ease
and speed of their rating.
Fully opposing atrophy ratings (one gold standard reader rated
normal, “zero”, the other pathological atrophy, “two”) were submitted
in 7.5% out of all 1200 individual regions.
Fig. 2 displays the distribution of ratings by the two gold standard
raters. As expected, atrophy was far more frequently detected in sam-
ples from patients with AD and FTD, conditions with a clear pattern of
atrophy detectable on MRI. Conversely, the frequency of atrophy in
LBD and the consensus of its distribution was far lower. Detection of
pathological atrophy was rarest in HC. Between the two gold standard
raters and across all ratings, a full consensus was reached in over one
third of all regions, reaching over 70% when the more liberal criterion
(partial or full agreement) was applied. Agreements between the gold
standard raters were highest for the hippocampus and lateral temporal
cortex and low for frontal and occipital cortex.
When comparing individual ratings to the gold standard (Fig. 3) we
found a similar pattern. Agreement was high for hippocampus, occipital
lobe and temporo-lateral regions but lower for frontal and parietal
cortices. Encouragingly, and irrespective of the criterion chosen for
agreement, inter-rater agreement was consistently above chance level.
All readers were significantly faster when rating images of the
second block, probably due to training effects. On average, the time
necessary to rate one volume was reduced from 110.8 s to 76.4 s
(−31%). Average time to complete one reading did neither increase
nor decrease significantly with the additional display of atrophy scores
(Fig. 4).
The intra-rater agreement measured by Cohen's Kappa (κ) of the
individual readers was often higher than that of the two gold standard
raters. The display of atrophy scores improved the intra-rater agree-
ment by 0.13 (range : 0.57 < κ < 0.87) and five out of seven readers
benefitted from the z-scores (Table 3).
The level of previous experience did not correlate with the diag-
nostic accuracy, neither with nor without the display of atrophy scores
(qualitatively shown on Fig. 3, Pearson correlation p > .05 (data not
shown)).
When evaluating the ability of z-scores to directly detect atrophy
independently from the individual rater, we found largest AUC for both
GM and CSF for temporo-lateral and hippocampus atrophy. Across all
regions, CSF based atrophy scores lead to a generally better dis-
crimination (Fig. 5). To evaluate the performance of these classifiers in
a hypothetical clinical setting, we used the known frequency of each
diagnostic group in a memory clinic and the frequency of region spe-
cific atrophy per diagnostic group as identified by two gold standard
raters (Fig. 2). The resulting prevalences are listed on Table 2. The
evaluation of the ability of the automated method to correctly identify
atrophy is depicted in Fig. 5. The high values for both SE and SP in the
hippocampus and temporo-lateral lobe area underscore the more reli-
able rating of this regions.
The population independent performance measures (i.e. SE and SP)
of the z-scores as well as the population dependent measures (i.e. PPV
and NPV) based on the optimal threshold obtained from the ROCs
(Fig. 5) are listed in Table 2. As expected, high NPV but low PPV are
reported for regions rarely affected by atrophy in the hypothetical
memory clinic sample (Table 2). As a consequence of the superior test
characteristics, performance was generally better when based on CSF
atrophy scores.
4. Discussion
Our study investigated a potential beneficial effect of computing
voxel-wise quantitative deviations of GM and CSF volumes to aid visual
readers in the detection of atrophy and to directly conclude on the
presence or absence of atrophy.
The pattern of atrophy as detected by the gold standard raters lar-
gely mirrored the expected disease specific pattern. Of note, the hip-
pocampus was frequently rated as borderline or atrophic in cases with
FTD and even more so than in cases with AD. This same pattern has
been reported for other rating studies (Harper et al., 2016) and is well
in line with VBM studies revealing no differences between FTD and AD
in e.g. the hippocampus region but only in the parietal cortex and
temporo-parietal junction (Du et al., 2007). Fig. 2 indicates that the
distribution of detected atrophy would often not allow a separation
between FTD and AD on the one hand and between LBD and HC on the
other. Overall, accuracy ratings of the seven individual readers were
satisfactory and higher in areas such as the hippocampus compared to
e.g. the frontal or parietal lobe, again well in line with previous work
(Harper et al., 2016). The readers were instructed to rate pathological
versus non-pathological atrophy and therefore needed to account for
age-related structural changes.
We found no beneficial effect of displaying z-scores, not even for
relatively unexperienced readers (trendlines in Fig. 3). This is in some
way surprising and contradicts the beneficial effect of the z-scores on
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Fig. 3. Accuracy of atrophy detections in relation to the gold standard reading. Blue indicates the accuracy using a strict definition of agreement while red displays
accuracy levels with a more liberal criterion (see main text for detail). The reported regions are indicated above each panel. Numbers in brackets indicate the
percentage of cases remaining after excluding those with conflicting ratings of the two gold standard readers. The readers (R1-R7) are ordered by increasing
experience from left to right. For each reader, the left bar indicated performance without and the right bar with z-scores. The trendlines indicate qualitatively the
relation between experience and accuracy without (dashed trendlines) and with (solid trendline) atrophy scores. The transparent horizontal blue and red line denote
the chance level 0.2 for full and 0.46 partial accuracy, respectively.
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Fig. 4. Left panel: Boxplots of individual reading times with (blue) and without (grey) atrophy score overlay. R1..R7 indicate the seven readers and GS-R1 and GS-R2
are the two gold standard readers. Note that GS-R1 and GS-R2 did not see the atrophy score maps. Right panel: Boxplots of individual reading times of first (grey) and
second (blue) presentation. Note that GS-R1 and GS-R2 performed all readings in a single block.
Fig. 5. Receiver-operator curves for each of 5 anatomical regions when pooled across both hemispheres separately for z-Scores indicating either grey or white matter
volume with atrophy scores larger than 2. We focused on cases with clear readings which were rated by both gold standard readers unanimously as normal or
atrophic. The percentage of cases fulfilling that criterion is reported in brackets (clear readings).
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time and accuracy subjectively perceived by the raters themselves. The
relatively poor agreement of the two gold standard readers (Fig. 2) in
regions such as the parietal cortex may have decreased our sensitivity to
detect a benefit of the z-scores. Furthermore, since the κ statistics takes
the frequency of levels into account, naïvely rating all cases with the
majority class would achieve a high accuracy but not a high κ value. An
alternative reason for the failure of detecting beneficial effects of z-
scores is the possibility that z-scores could encourage false positive or
negative atrophy ratings. Z-score deviations were not scaled to mimic
the gold standard raters and the individual raters did not know the
optimal cut-point. In any case, the increase in intra-rater agreement
with the display of z-scores and regional statistics clearly shows that
those influenced the atrophy rating and were not ignored. However, an
increase in intra-rater agreement on its own is not useful if not asso-
ciated with more accurate ratings. While VBM is a relatively robust
method, there are several sources that can introduce a bias. Image ar-
tefacts are generally relevant here but potentially less so in our data set
given that it was largely derived from well controlled studies. However,
imperfect image registration or variations in the individual cortical
folding pattern could explain discrepancies between z-scores and an
experienced rater and illustrate that z-scores may not always indicate
atrophy in a biological sense. Of note, major errors in image registration
are become obvious to the raters as deviation maps were overlayed on
the individual brain scan. Although both hemispheres were rated se-
parately, we pooled across both hemispheres. This is justified by studies
showing no systematic asymmetry of atrophy across neurodegenerative
diseases (Minkova et al., 2017). On the other hand, individual cases
may show asymmetric atrophy e.g. the language subtype of FTD is ty-
pically associated with atrophy of the left temporo-lateral cortex and
pooling across hemispheres may have levelled out the clearer left-
hemisphere readings.
We found no effect of displaying deviation scores on the speed of
rating. Displaying voxel-wise deviations increase the amount of in-
formation which could require extra time. On the other hand, provided
information could increase clarity of the rating. Our results indicate
that these two factors may outweigh each other. As mentioned already,
readers subjectively perceived an increase in rating speed resulting
from the displayed scores which may indicate that they would be more
willing to rate scans in an actual clinical setting when z-scores were
displayed alongside.
When evaluating the usefulness of region-specific average volume
deviations irrespective of the individual readers, we found large AUCs
particularly when deviations where computed from the CSF segment
(Fig. 5). The CSF segment poses more clearly defined boundaries
compared to the GM-segment which may explain favourable perfor-
mance. While several visual rating scales already include an evaluation
of CSF spaces (Davies et al., 2009; Koedam et al., 2011; Scheltens et al.,
1992), our study indicates that changes in the CSF segment should also
be the basis for the automated analysis of GM loss. When applying the
classifier to a hypothetical clinical setting, the resulting PPV and NPV
were frequently above 0.9 and may indicate clinical usefulness de-
pending on the exact set of consequences. Although all regions per-
formed well (minimal AUC for CSF-based classifier= 0.84), best per-
formance was reached for the lateral and medial temporal lobes. Of
note, this analysis was restricted to regions either clearly normal or
clearly atrophic as judged by the gold standard raters which lead to the
exclusion of up to 27% of cases for regions such as the parietal and
frontal cortex. It is likely that the exclusion of borderline or incon-
sistently rated cases resulted in more optimistic estimates for the AUCs
and the resulting PPV and NPV values an effect probably made more
severe by the employed study sample. We used the volume of voxels
with a z-score deviating by more than two standard deviations as a
metric to quantify region specific deviations in a single variate. This
metric was chosen as it resembles the visualization provided to the
human raters where we also used a minimum deviation of two standard
deviations.
In summary, we found beneficial effect from displaying voxel-wise
deviations scores to aid human visual reading of cerebral MR-scans to
be limited to intra-rater reliability and the subjective speed and accu-
racy. On the other hand our results on the detection accuracy of z-scores
on their own motivate the automated analysis of z-scores based on the
CSF segment separately from a visual rating. The exact threshold should
be based on the local setting where a high sensitivity may outweigh an
increasing number of false positives.
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